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Preexistent tumor inflammation is associated with superior
clinical benefit from immunotherapies targeting immune
checkpoints, calling for development of strategies that can
induce tumor immune infiltration. To this end, therapy
with oncolytic viruses (OV) presents an attractive strategy,
though clinical development of OV’s has been largely ham-
pered by their poor systemic delivery to metastatic sites.
Newcastle Disease Virus (NDV) is a member of the Avula-
virus genus in the Paramyxoviridae family, which has been
shown to infect a number of avian species, but to cause no
disease in humans. For the past 50 years, NDV has been
shown to be an effective oncolytic agent, causing specific
lysis of cancerous but not normal cells. During an effort to
develop a systemically-active oncolytic NDV, we found
that localized therapy with the virus induced systemic
tumor inflammatory response with activated effector but
not regulatory T cell infiltration in distant tumors without
virus spread to these sites. Combination therapy with loca-
lized NDV and systemic CTLA-4 or PD-1 blockade led to
antigen-dependent distant tumor rejection in both NDV-
susceptible (B16) and resistant (TRAMP C2 and CT26)
tumor models, and protected the animals from further
tumor re-challenge. This effect was associated with marked
distant tumor infiltration with activated effector, but not
regulatory T cells, and was dependent on CD8 and NK
cells, and types I and II interferons. To further enhance
the T cell effector function in the treated tumors, we
genetically engineered a panel of oncolytic NDV’s expres-
sing co-stimulatory ligands. We specifically focused on the
inducible co-stimulator (ICOS), which in clinical trials has
been associated with improved clinical benefit from anti-
CTLA-4 therapy. When used in combination with anti-
CTLA-4 therapy, NDV expressing ICOS ligand (NDV-
ICOSL) induced rejection of distant tumors more
efficiently than the parental virus, leading to long-term ani-
mal survival in the majority of animals and protection
against tumor re-challenge. Our findings uncover the
mechanisms of NDV-induced systemic anti-tumor immune
responses and provide a strong rationale for clinical
exploration of combination therapies of engineered oncoly-
tic viruses with agents targeting immune checkpoints.
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